TD Cowen analyst Yaron Werber has maintained their bullish stance on ROIV stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yaron Werber has given his Buy rating due to a combination of factors that highlight the potential of Roivant Sciences’ drug brepocitinib. The drug has shown promising results in its Phase 3 VALOR study for treating dermatomyositis (DM), achieving statistically significant efficacy across all key endpoints. This includes a notable improvement in the Total Improvement Score (TIS) and Cutaneous Dermatomyositis Activity and Severity Index (CDASI) compared to placebo. Brepocitinib’s performance suggests it could become the best-in-class second-line standard of care in DM, with projected peak sales reaching $1.3 billion in the US and Japan by 2033.
Moreover, the drug’s oral, once-daily dosing and favorable tolerability profile make it an attractive option for patients and physicians, especially in a market with limited approved therapies. The unmet need in DM, affecting a significant number of patients, further supports the potential for broad adoption of brepocitinib. Roivant’s management plans to file for FDA approval in early 2026, with expectations of approval by late 2026 or early 2027. These factors collectively underpin Werber’s optimistic outlook and Buy rating for Roivant Sciences.
According to TipRanks, Werber is a 5-star analyst with an average return of 16.3% and a 59.32% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Roivant Sciences, and Ionis Pharmaceuticals.
In another report released today, Guggenheim also maintained a Buy rating on the stock with a $21.00 price target.